Discover if this is a suitable investor for your startup. If they are we'll make a warm introduction for free. Otherwise, we'll connect you with matching investors.
KdT Ventures is an early-stage venture capital firm founded in 2017 and based in the United States. The firm focuses on investing in frontier science, particularly in chemistry and biology, to tackle significant global challenges through technology. KdT Ventures currently manages a portfolio of 9 companies.
KdT Ventures invests in early-stage companies that are commercializing scientific advancements at the molecular level. Their investment thesis emphasizes the integration of next-generation sequencing, artificial intelligence, and hyper-scale computing to model and alter biological systems, primarily in sectors like healthcare, biotech, and materials science.
Notable portfolio companies include PathAI, which enhances diagnostic accuracy through data-driven pathology analysis; Tavros Therapeutics, focused on next-generation cancer therapies; and Remedy Robotics, which develops software for autonomous navigation in vascular surgical robots. Other companies include Elegen, Checkerspot, STRM.BIO, Solugen, Dyno Therapeutics, and Debut Biotechnology.
Submit through their form at https://kdtvc.com/contact.
KdT Ventures often leads investment rounds, particularly in pre-seed and seed stages, to help shape the direction of their portfolio companies.
The firm is open to follow-on investments, especially if the company continues to align with their investment thesis and demonstrates significant progress.
Specific details about the fund size are not publicly disclosed, but KdT Ventures focuses on early-stage investments across multiple sectors.
All trademarks, logos and brand names are the property of their respective owners. All company, product and service names used in this website are for identification purposes only. Use of these names, trademarks, and brands does not imply endorsement.